Literature DB >> 28434647

Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries).

Agata Tymińska1, Agnieszka Kapłon-Cieślicka2, Krzysztof Ozierański1, Michał Peller1, Paweł Balsam1, Michał Marchel1, Maria G Crespo-Leiro3, Aldo P Maggioni4, Ewa A Jankowska5, Jarosław Drożdż6, Krzysztof J Filipiak1, Grzegorz Opolski1.   

Abstract

Anemia is a commonly observed co-morbidity in heart failure (HF). The aim of the study was to assess prevalence, risk factors for, and effect of anemia on short- and long-term outcomes in HF. The study included 1,394 Caucasian patients hospitalized for HF, with known hemoglobin concentration on hospital admission, participating in 2 HF registries of the European Society of Cardiology (Pilot and Long-Term). Anemia was defined as hemoglobin concentration of <13 g/dl for men and <12 g/dl for women. Primary end points were (1) all-cause death at 1 year and (2) a composite of all-cause death and rehospitalization for HF at 1 year. Secondary end points included inter alia death during index hospitalization. In addition, we investigated the effect of changes in hemoglobin concentration during hospitalization on prognosis. Anemia occurred in 33% of patients. Predictors of anemia included older age, diabetes, greater New York Heart Association class at hospital admission and kidney disease. During 1-year follow-up, 21% of anemic and 13% of nonanemic patients died (p <0.0001). Combined primary end point occurred in 45% of anemic and in 33% of nonanemic patients (p <0.0001). Anemia was strongly predictive of all the prespecified clinical end points in univariate analyses but not in multivariate analyses. Changes in hemoglobin concentration during hospitalization had no effect on 1-year outcomes. In conclusion, anemia was present in 1/3 of patients with HF. Mild-to-moderate anemia seems more a marker of older age, worse clinical condition, and a higher co-morbidity burden, rather than an independent risk factor in HF.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28434647     DOI: 10.1016/j.amjcard.2017.03.035

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Significance of congestive heart failure as a cause of pleural effusion: Pilot data from a large multidisciplinary teaching hospital.

Authors:  Piotr Korczyński; Katarzyna Górska; Damian Konopka; Dżamila Al-Haj; Krzysztof J Filipiak; Rafał Krenke
Journal:  Cardiol J       Date:  2018-11-08       Impact factor: 2.737

2.  Survival time to complications of congestive heart failure patients at Felege Hiwot comprehensive specialized referral hospital, Bahir Dar, Ethiopia.

Authors:  Nuru Mohammed Hussen; Demeke Lakew Workie; Hailegebrael Birhan Biresaw
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

3.  Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand.

Authors:  Kittayaporn Chairat; Wipharak Rattanavipanon; Krittika Tanyasaensook; Busba Chindavijak; Suvatna Chulavatnatol; Surakit Nathisuwan
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-30

4.  Anemia in severe heart failure patients: does it predict prognosis?

Authors:  Tamrat Befekadu Abebe; Eyob Alemayehu Gebreyohannes; Akshaya Srikanth Bhagavathula; Yonas Getaye Tefera; Tadesse Melaku Abegaz
Journal:  BMC Cardiovasc Disord       Date:  2017-09-16       Impact factor: 2.298

5.  The prognosis of heart failure patients: Does sodium level play a significant role?

Authors:  Tamrat Befekadu Abebe; Eyob Alemayehu Gebreyohannes; Yonas Getaye Tefera; Akshaya Srikanth Bhagavathula; Daniel Asfaw Erku; Sewunet Admasu Belachew; Begashaw Melaku Gebresillassie; Tadesse Melaku Abegaz
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

6.  Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.

Authors:  Agata Tymińska; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Monika Budnik; Anna Wancerz; Piotr Sypień; Michał Peller; Paweł Balsam; Grzegorz Opolski; Krzysztof J Filipiak
Journal:  Dis Markers       Date:  2019-10-10       Impact factor: 3.434

7.  The Prognostic Significance of Anemia in Patients With Heart Failure: A Meta-Analysis of Studies From the Last Decade.

Authors:  Haijiang Xia; Hongfeng Shen; Wei Cha; Qiaoli Lu
Journal:  Front Cardiovasc Med       Date:  2021-05-13

8.  Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction- Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data from European Society of Cardiology Heart Failure Registries).

Authors:  Agata Tymińska; Krzysztof Ozierański; Paweł Balsam; Cezary Maciejewski; Anna Wancerz; Emil Brociek; Michał Marchel; Maria G Crespo-Leiro; Aldo P Maggioni; Jarosław Drożdż; Grzegorz Opolski; Marcin Grabowski; Agnieszka Kapłon-Cieślicka
Journal:  Biology (Basel)       Date:  2022-02-21

9.  Association of On-Admission Anemia With 1-Year Mortality in Patients Hospitalized With Acute Heart Failure: Results From the HERO Study.

Authors:  Junlei Li; Chao Jiang; Yiwei Lai; Li Li; Xiaoyan Zhao; Xiaofang Wang; Ling Li; Xin Du; Changsheng Ma; Jianzeng Dong
Journal:  Front Cardiovasc Med       Date:  2022-05-04

10.  Outcomes of patients with anemia and renal dysfunction in hospitalized heart failure with preserved ejection fraction (from the CN-HF registry).

Authors:  Xuejuan Jin; Juan Cao; Jun Zhou; Yanyan Wang; Xueting Han; Yu Song; Yuyuan Fan; Zhenyue Chen; Dingli Xu; Xinchun Yang; Wei Dong; Liwen Li; Li Chen; Qiaoqing Zhong; Micheal Fu; Kai Hu; Jingmin Zhou; Junbo Ge
Journal:  Int J Cardiol Heart Vasc       Date:  2019-08-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.